Swiss National Bank Boosts Holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

Share on StockTwits

Swiss National Bank grew its holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 2.2% in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 168,900 shares of the company’s stock after purchasing an additional 3,700 shares during the quarter. Swiss National Bank owned 0.18% of Neurocrine Biosciences worth $14,260,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also bought and sold shares of the company. Dimensional Fund Advisors LP increased its holdings in shares of Neurocrine Biosciences by 3.7% in the fourth quarter. Dimensional Fund Advisors LP now owns 173,257 shares of the company’s stock worth $12,369,000 after purchasing an additional 6,149 shares during the period. Geode Capital Management LLC increased its holdings in shares of Neurocrine Biosciences by 4.2% in the fourth quarter. Geode Capital Management LLC now owns 907,292 shares of the company’s stock worth $64,789,000 after purchasing an additional 36,508 shares during the period. Nisa Investment Advisors LLC increased its holdings in shares of Neurocrine Biosciences by 6.4% in the first quarter. Nisa Investment Advisors LLC now owns 5,965 shares of the company’s stock worth $526,000 after purchasing an additional 358 shares during the period. Brinker Capital Inc. increased its holdings in shares of Neurocrine Biosciences by 4.9% in the first quarter. Brinker Capital Inc. now owns 10,352 shares of the company’s stock worth $912,000 after purchasing an additional 483 shares during the period. Finally, Exane Derivatives increased its holdings in shares of Neurocrine Biosciences by 901.4% in the first quarter. Exane Derivatives now owns 4,857 shares of the company’s stock worth $428,000 after purchasing an additional 4,372 shares during the period. 94.45% of the stock is owned by institutional investors and hedge funds.

NASDAQ NBIX opened at $97.59 on Friday. The company has a 50-day simple moving average of $91.19 and a two-hundred day simple moving average of $84.60. The company has a quick ratio of 7.32, a current ratio of 7.44 and a debt-to-equity ratio of 0.96. Neurocrine Biosciences, Inc. has a 12-month low of $64.72 and a 12-month high of $126.98. The firm has a market cap of $9.01 billion, a price-to-earnings ratio of 443.59, a PEG ratio of 5.12 and a beta of 1.32.

Neurocrine Biosciences (NASDAQ:NBIX) last posted its quarterly earnings results on Monday, July 29th. The company reported $0.37 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.24 by $0.13. Neurocrine Biosciences had a net margin of 2.98% and a return on equity of 0.46%. The business had revenue of $183.58 million during the quarter, compared to analyst estimates of $161.79 million. During the same period in the prior year, the business posted ($0.07) earnings per share. The company’s revenue was up 89.5% on a year-over-year basis. Equities analysts expect that Neurocrine Biosciences, Inc. will post 0.8 earnings per share for the current fiscal year.

Several research analysts have recently weighed in on the stock. Zacks Investment Research raised shares of Neurocrine Biosciences from a “hold” rating to a “buy” rating and set a $97.00 price target on the stock in a report on Wednesday, July 31st. BidaskClub upgraded shares of Neurocrine Biosciences from a “hold” rating to a “buy” rating in a research report on Thursday, August 8th. Stifel Nicolaus set a $113.00 target price on shares of Neurocrine Biosciences and gave the stock a “buy” rating in a research report on Monday, July 15th. Piper Jaffray Companies upped their target price on shares of Neurocrine Biosciences from $103.00 to $111.00 and gave the stock an “overweight” rating in a research report on Tuesday, July 30th. Finally, Oppenheimer started coverage on shares of Neurocrine Biosciences in a research report on Tuesday, July 16th. They issued an “outperform” rating and a $100.00 target price for the company. Three research analysts have rated the stock with a hold rating and twenty have given a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus target price of $107.15.

In other Neurocrine Biosciences news, CEO Kevin Charles Gorman sold 80,000 shares of the company’s stock in a transaction dated Thursday, August 8th. The shares were sold at an average price of $95.31, for a total transaction of $7,624,800.00. Following the completion of the sale, the chief executive officer now directly owns 468,508 shares in the company, valued at $44,653,497.48. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, insider Haig P. Bozigian sold 19,297 shares of the stock in a transaction dated Friday, May 31st. The stock was sold at an average price of $85.02, for a total transaction of $1,640,630.94. Following the sale, the insider now owns 161,273 shares of the company’s stock, valued at $13,711,430.46. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 211,897 shares of company stock valued at $19,536,555. Company insiders own 4.30% of the company’s stock.

Neurocrine Biosciences Profile

Neurocrine Biosciences, Inc discovers and develops pharmaceuticals for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company offers INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor (VMAT2), which is used for the treatment of movement disorders; ORILISSA, a gonadotropin-releasing hormone (GnRH) antagonist for use in women's health.

Featured Story: Convertible Shares

Institutional Ownership by Quarter for Neurocrine Biosciences (NASDAQ:NBIX)

Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Van ECK Associates Corp Acquires 32,791 Shares of Invesco Quality Municipal Income Trust
Van ECK Associates Corp Acquires 32,791 Shares of Invesco Quality Municipal Income Trust
Van ECK Associates Corp Purchases 33,873 Shares of Invesco Municipal Trust
Van ECK Associates Corp Purchases 33,873 Shares of Invesco Municipal Trust
Van ECK Associates Corp Has $3.22 Million Stake in GasLog Partners LP Unit
Van ECK Associates Corp Has $3.22 Million Stake in GasLog Partners LP Unit
Van ECK Associates Corp Has $3.23 Million Holdings in Teekay Lng Partners, L.P.
Van ECK Associates Corp Has $3.23 Million Holdings in Teekay Lng Partners, L.P.
Van ECK Associates Corp Grows Holdings in Invesco Trust for Investment GradeMncpls
Van ECK Associates Corp Grows Holdings in Invesco Trust for Investment GradeMncpls
Van ECK Associates Corp Cuts Position in Telekomnks Indn Prsr Tbk Prshn Prsrn-ADR
Van ECK Associates Corp Cuts Position in Telekomnks Indn Prsr Tbk Prshn Prsrn-ADR


© 2006-2019 Ticker Report